2002results about "Ester active ingredients" patented technology

The invention relates to the technical field of food, in particular to diglyceride for reducing triglyceride, cholesterol and uric acid as well as a biological enzyme preparation method and application of the diglyceride. The preparation method comprises the following steps: (1) adding water and glycerol into vegetable oil, and then adding immobilized lipase to react to obtain a reactant; (2) centrifuging reactants, collecting a light-phase product, carrying out molecular distillation, and collecting a heavy-phase product to obtain diglyceride; the immobilized lipase comprises lipase and a carrier, the carrier comprises loofah sponge, soybean meal and bentonite, and the mass ratio of the loofah sponge to the soybean meal to the bentonite is 1: (2-4): (3-6). The method has the advantages that the effects of reducing triglyceride, total cholesterol and uric acid are relatively good, and the yield and the purity are relatively high.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to enhance natural healing ability of a biological body and to treat a disease in a mammal, and to mitigate side effects of cancer treatments.

The invention relates to the technical field of probiotics, in particular to a combined fungicide for improving Alzheimer's disease and application of the combined fungicide. The combined microbial agent is prepared from lactobacillus gasseri LFLG-245 and inactivated Ackermania muciniphila AKKLF (Ackermania muciniphila AKKLF); the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the lactobacillus gasseri LFLG-245 is CGMCC (China General Microbiological Culture Collection Center) No.33952. The lactobacillus gasseri LFLG-245 has the advantages that the lactobacillus gasseri LFLG-245 is preserved in the China General Microbiological Culture Collection Center; the Akkermansia muciniphila AKKLF is preserved in the China General Microbiological Culture Collection Center on March 24, 2025, and the preservation number of the Akkermansia muciniphila AKKLF is CGMCC (China General Microbiological Culture Collection Center) No.33955. The Akkermansia muciniphila AKKLF disclosed by the invention has the advantages that the Akkermansia muciniphila AKKLF can be applied to the field of biological The combined microbial agent provided by the invention can improve the Alzheimer's disease.

The invention belongs to the technical field of grease preparation, and particularly relates to a preparation method and application of diglyceride oil with a weight reducing effect. Comprising the following steps: firstly, adding grease into a basic nutrient solution, adding strains for fermentation, and filtering to obtain a glycolysis product; adding glycerol into the glycolysis product, carrying out lipase esterification reaction, and carrying out centrifugal separation to obtain an oil phase; the method comprises the following steps: degrading triglyceride by adopting dominant strain fermentation, then adding glycerol, and carrying out esterification reaction under the action of dominant compound lipase to obtain the diglyceride oil. According to the method, the 1, 3-diglyceride can be selectively generated, the proportion of dominant grease of the 1, 3-diglyceride can be increased, and research shows that the prepared diglyceride oil has good weight reduction and fat reduction effects and has a good application prospect.

Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

Compositions for delivering ketone bodies to a subject include one or more beta-hydroxybutyrate salts, one or more acetoacetate salts, beta-hydroxybutyric acid, and optionally acetoacetic acid. The compositions may optionally include one or more ketone body esters, such as one or more beta-hydroxybutyrate esters and / or one or more acetoacetate esters. An example composition contains about 2% to about 98% on a molar basis of the one or more beta-hydroxybutyrate salts and the one or more acetoacetate salts, about 2% to about 98% on a molar basis of the beta-hydroxybutyrate free acid and optionally the acetoacetate free acid, and optionally about 2% to about 98% on a molar basis of one or more ketone body esters.

Disclosed herein are compositions of matter suitable for use in foods, feeds, pharmaceuticals and cosmetic care products, the compositions of matter comprising a retinoid component and fermentation residues thereof. In embodiments, the retinoid component is present in a weight ratio relative to the fermentation residue of 4: 1 or greater, where the retinoid contains cis-isomer and trans-isomer, where the cis-isomer is present in an amount of less than 3% by weight relative to the entire isomer mixture. Preferably, the composition is bio-based. Also described are biotechnological methods for producing the compositions otherwise described, as well as additional methods for processing such compositions into more stable, more commercially acceptable forms. Finally, foods, feeds, pharmaceuticals, and cosmetic care products incorporating the compositions described herein are also disclosed.

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

A pharmaceutical composition comprising a metal channel activator and a glutamic acid modulator is provided. Also provided is a method of treating depressive disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a neurological or neurodegenerative disorder comprising administering the pharmaceutical composition. Also provided is a method of treating a pain disorder comprising administering the pharmaceutical composition.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

Provided is an insulin secretion-promoting agent comprising, as an active ingredient, a triglyceride represented by the following formula (I):wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. An insulin secretion-promoting action of the pentadecanoic acid triglyceride at the time of elevated blood glucose level is discovered, and pharmaceuticals and health foods for improving blood glucose level and diabetes are provided using this triglyceride.

The invention provides a Falcarindiol derivative, preparation thereof and application of the Falcarindiol derivative in preparation of medicines for preventing and / or treating bone diseases. The structural general formula of the Falcarindiol derivative is as shown in formula I in the specification. Experimental results show that the Falcarindiol derivative can significantly inhibit osteoclast differentiation, and is expected to be used for preparing novel drugs for preventing and / or treating osteoporosis, osteoporosis fracture, osteolysis, periprosthetic osteolysis, tumor bone metastasis, inflammatory bone loss, periodontitis inflammatory bone resorption and other bone diseases. # imgabs0 #

A composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and an antioxidant in reduced percentages by weight, and related methods for treatment of arthritis and of inflammatory joint and musculoskeletal pain. Furthermore composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and, optionally, an antioxidant, and related treatment methods for protecting the gastric mucosa and for regulating the blood glucose levels. Additionally, a method is described for preparing the at least one cetylated fatty acid or mixture of cetylated fatty acids and for preparing compositions comprising the cetylated fatty acids and the antioxidant.

The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and / or frequency of ralinepag and / or riociguat, reduced doses and / or frequency of ralinepag and / or treprostinil, and reduced doses and / or frequency of ralinepag and / or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and / or iloprost monotherapies.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention discloses a method for preparing uric acid-lowering diglyceride by enzymatic hydrolysis, as well as its product and application, belonging to the technical field of diglyceride production. The method comprises the following steps: (1) mixing vegetable oil, glycerol, water, and an enzyme preparation to react to obtain a reaction solution; (2) allowing the reaction solution to stand for stratification and collecting the supernatant; (3) distilling and separating the supernatant, decolorizing, and deodorizing the supernatant to obtain diglyceride; the enzyme preparation in step (1) comprises lipase, esterase, and phospholipase C in a weight ratio of 5-10:0.1-0.3:1. Compared with the existing technology, the method of the present invention is simple and low-cost, and the prepared diglyceride has greater advantages in lowering uric acid.

The invention relates to the technical field of liposomes, in particular to a lutein ester-fumaric acid composite liposome with high bioavailability as well as a preparation method and application of the lutein ester-fumaric acid composite liposome. The preparation method of the lutein ester-fumaric acid composite liposome comprises the following steps: mixing lutein ester with oil to obtain a phase A; adding phospholipid, cholesterol and vitamin E into the phase A, and then carrying out ultrasonic dispersion treatment to obtain a phase B; fumaric acid and water are added into the phase B, and then high-pressure homogenization treatment, high-pressure microjet treatment and freeze-drying treatment are sequentially performed to obtain the lutein ester-fumaric acid composite liposome. The lutein ester-fumaric acid composite liposome with high bioavailability has the advantages of small average particle size, high Zeta potential, high encapsulation efficiency, high bioavailability, high solubility and excellent stability, and has potential application prospects in preparation of foods, medicines or health care products with eye protection functions.

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient.

Provided is a collagen production promoter comprising, as an active ingredient, a triglyceride represented by the following formula (I), wherein R1, R2 and R3 each denotes a saturated fatty acid residue, at least one of which is a pentadecanoic acid residue. The triglyceride comprising the pentadecanoic acid promotes the production of skin fibroblasts and collagen, and can be used as a topical skin care composition and a beauty food or beverage for improving the condition of skin.

The present invention relates to methods for alleviating symptoms selected from the group consisting of fatigue and frailty associated with aging, skin aging, muscle weakness, statin-associated muscle symptoms, cardiovascular diseases, kidney diseases, and CoQ10 depletion and mitochondrial failure associated with adult neurodegenerative diseases. The present invention further relates to methods for improving mitochondrial function in the end organs.

The present invention relates to the use of cannabidiol (CBD) in the treatment of Sturge Weber syndrome. CBD ap-pears particularly effective in reducing all types of seizures and non-seizure symptoms in patients suffering with Sturge Weber syndrome. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocan-nabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Compounds of formula (I) and methods of inhibiting viral replication in a biological sample or a patient, methods of reducing the amount of virus in a biological sample or a patient, and methods of treating a viral infection in a patient, comprising administering to the biological sample or the patient an effective amount of a compound represented by formula (I), a compound of Table A or B, or a pharmaceutically acceptable salt thereof. [Formula 1] JPEG2023521116000242.jpg18138

The invention provides application of a copper death inducer in preparation of a medicine for treating osimertinib-resistant non-small cell lung cancer, and belongs to the technical field of treatment of non-small cell lung cancer. According to the invention, through high-throughput drug screening, the copper death inducer copper diethyl dithiocarbamate (CuET) and osimertinib are combined for use, so that a remarkable synergistic anti-cancer effect is achieved; furthermore, through detection of a wild type and osimertinib drug-resistant cell line model, an osimertinib sensitive and drug-resistant patient-derived organoid and a mouse xenotransplantation model, it is found that the anti-tumor effect of osimertinib can be remarkably enhanced through copper death induction, and osimertinib drug resistance is overcome. According to the technical scheme provided by the invention, osimertinib drug-resistant non-small cell lung cancer cells can be effectively killed, the curative effect of osimertinib in sensitive and drug-resistant models is remarkably enhanced, and an application scene is provided for copper death in tumor treatment.

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

The invention discloses a female private part composite bacteriostatic agent and a preparation method thereof, and relates to the technical field of female care products. The female private part compound bacteriostatic agent is prepared from the following raw materials in percentage by weight: 0.2 to 0.5 percent of cortex phellodendri extract, 0.2 to 0.5 percent of radix sophorae flavescentis extract, 0.05 to 0.1 percent of tanshinone extract, 0.05 to 0.1 percent of fructus cnidii extract, 0.5 to 1.2 percent of cranberry extract, 0.02 to 0.04 percent of chlorhexidine gluconate, 0.02 to 0.04 percent of chlorhexidine acetate, 0.08 to 0.2 percent of glycerol monolaurate, 0.3 to 0.9 percent of lactic acid, 0.3 to 0.9 percent of probiotic microcapsules, 1 to 2 percent of compound amino acid surfactant, 0.1 to 0.5 percent of vitamin E and the balance of water. 0.1-0.3% of a preservative, 2-4% of glycerol and the balance of water. The antibacterial health-care product has an excellent antibacterial effect, and can effectively regulate the micro-ecological balance of the private parts of women.

A composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and an antioxidant in reduced percentages by weight, and related methods for treatment of arthritis and of inflammatory joint and musculoskeletal pain. Furthermore a composition is described comprising a mixture of at least one cetylated fatty acid or a mixture of cetylated fatty acids and, optionally, an antioxidant, and related treatment methods for protecting the gastric mucosa and for regulating the blood glucose levels. Additionally, a method is described for preparing the at least one cetylated fatty acid or mixture of cetylated fatty acids and for preparing compositions comprising the cetylated fatty acids and the antioxidant.

The present invention relates to a novel compound useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAA receptor complex.